Track record

This article's stated reasonA straight momentum run to a fresh all-time high left no lens willing to call it a buy — all six now want the July 30 print before adding conviction.

This article's stated reasonThe prior panel leaned WAIT with high conviction because two bullish voices (The GARP Operator and The Scuttlebutt Growth Investor) faced two skeptics and two neutrals, leaving no clear edge. This time, The Disruptive-Innovation Seeker and The Asymmetric Bargainer rotated off, replaced by The Macro Opportunist (neutral-leaning-bullish) and The Margin-of-Safety Hunter (emphatically bearish), which deepened the business-quality split rather than resolving it. The stock's 6.4% rally from $483 to $514 since early August did nothing to close the valuation gap — The Intrinsic-Value Modeler's DCF still points to ~$395 fair value, The Margin-of-Safety Hunter's The Margin-of-Safety Hunter Number is still $28, and The Forensic Skeptic's bear case of $300-$400 still looms. The deadlock holds because the business story got incrementally better (Q2 beat, raised guidance) but the price moved up with it, leaving the fundamental dispute exactly where it was.

This article's stated reasonPrice round-tripped through a marginal new high and back through the $226-230 support shelf; even the now-5-of-6 bullish panel is withholding full conviction until the July 30 print.

This article's stated reasonThe prior WAIT verdict at $23.15 reflected a panel split where the business was still being debated — a single bullish voice (The Disruptive-Innovation Seeker) held a constructive optionality view, and the panel composition included The Macro Opportunist and The Moat Compounder, who were more open to the infrastructure thesis. This SELL verdict at $22.32 reflects a hardened bearish consensus: the addition of The Activist Catalyst and The Quality Rationalist — both frameworks that demand capital discipline and insider alignment — eliminated any residual willingness to give management the benefit of the doubt, while the lone cautious voice (The Disruptive-Innovation Seeker) now explicitly conditions any constructive view on August 4 catalyst confirmation rather than maintaining a standing constructive posture.

This article's stated reasonThe prior WAIT at $71.77 reflected a panel that included The Margin-of-Safety Hunter, whose price-discipline framework left room for a bullish turn if the stock approached intrinsic-value estimates. The 26% rally to $90.67, without any improvement in the underlying business fundamentals, eliminated that price-based counterargument entirely, while the addition of The Activist Catalyst and The Scuttlebutt Growth Investor reinforced the consensus: this is a fundamentally broken business model where a higher stock price only widens the downside risk.

This article's stated reasonA rally stalled just below the 200-day moving average, and a panel reshuffle left no seat bullish — the Q2 print now decides whether Claude Design expands or erodes Figma's surface.

This article's stated reasonA pullback off a twice-rejected $373-375 shelf reads as pre-earnings de-risking, not a broken thesis — Cloud margins and free cash flow in the July 21 print are what the panel is watching.

This article's stated reasonThe prior panel (July 2026) issued a WAIT at $28.09, with six archetypes seeing enough uncertainty to stay on the sidelines. This time, the addition of The Asymmetric Bargainer sharpened the frame: the downside math is now so lopsided — a potential 60–80% loss versus a capped 30% gain — that even waiting at $28 is costly. Meanwhile, fundamentals have continued to erode with another quarter of near-zero growth and widening GAAP losses, and no archetype stepped forward to defend the business. The verdict flipped from WAIT to SELL not because the price moved meaningfully, but because the passage of time revealed that the deterioration is structural, not transitional.

This article's stated reasonThe prior panel (Aug 8) issued a unanimous SELL at $101.65, driven by a lineup weighted toward intrinsic-value and quality frameworks that saw no margin of safety at any nearby price. Today's panel removes the Activist Catalyst and Disruptive-Innovation Seeker and adds the Macro Opportunist, shifting the split from unanimous bearishness to a PRICE/TIMING-dominant WAIT: two voices remain structurally bearish, but three others now see a tradable setup if price pulls into the $95-97 zone. The verdict moves from SELL to WAIT not because the business improved materially in seven days, but because the panel's composition now includes voices that frame the objection as \"wrong price\" rather than \"broken business,\" and that distinction opens a specific entry level where the call flips.

This article's stated reasonThe previous panel leaned WAIT at $32.97 because The Forensic Skeptic and The Quality Rationalist had open concerns about earnings quality and competitive durability. Since then, the stock dropped nearly 12% to $29.06 while management delivered a Q2 print showing a definitive operating-income swing from negative to positive $700 million and explicitly guided for a Q3 revenue recovery. The Forensic Skeptic exited the panel, and the remaining voices — now joined by The Margin-of-Safety Hunter — see a deeper margin of safety at the lower price, flipping the consensus from WAIT to BUY: the business improved, the price got cheaper, and the old skeptics' objections no longer carry a seat at the table.